Park Sungha, Kario Kazuomi, Park Chang Gyu, Huang Qi Fang, Cheng Hao Min, Hoshide Satoshi, Wang Ji Guang, Chen Chen Huan
Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, Korea.
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan.
Yonsei Med J. 2016 Nov;57(6):1307-11. doi: 10.3349/ymj.2016.57.6.1307.
Recently, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure (BP) trial enrolled 4733 participants with type 2 diabetes and randomized them to a target systolic blood pressure (SBP) of less than 120 mm Hg or 140 mm Hg. Despite the significant difference in the achieved SBP, there was no significant difference in the incidence of primary outcomes. Based on this evidence, the target SBP for diabetics has been revised in the majority of major guidelines. However, there is a steeper association between SBP and stroke in Asians than other ethnicities, with stroke being the leading cause of cardiovascular mortality. This suggests that target BP in the Asian region should be tailored towards prevention of stroke. In the ACCORD study, the intensive BP treatment was associated with significant reductions in both total stroke and non-fatal stroke. The results from the ACCORD study are supported by a subgroup analysis from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study, which showed that, in diabetic patients, the risk of stroke continues to decrease to a SBP value of 115 mm Hg with no evidence of J curve. As diabetes is highly associated with underlying coronary artery disease, there is a justified concern for adverse effects resulting from too much lowering of BP. In a post hoc analysis of 6400 diabetic subjects enrolled in the International Verapamil SR-Trandolapril (INVEST) study, subjects with SBP of less than 110 mm Hg were associated with a significant increase in all-cause mortality. In the ONTARGET study, at any levels of achieved SBP, diastolic blood pressure (DBP) below 67 mm Hg was associated with increased risk for cardiovascular outcomes. As such, a prudent approach would be to target a SBP of 130-140 mm Hg and DBP of above 60 mm Hg in diabetics with coronary artery disease. In conclusion, hypertension, in association with diabetes, has been found to be significantly correlated with an elevated risk for cardiovascular events. As the association between stroke and BP is stronger in Asians, compared to other ethnicities, consideration should be given for a target BP of 130/80 mm Hg in Asians.
最近,糖尿病心血管风险控制行动(ACCORD)血压试验招募了4733名2型糖尿病患者,并将他们随机分为收缩压(SBP)目标值低于120 mmHg或140 mmHg两组。尽管实现的SBP存在显著差异,但主要结局的发生率并无显著差异。基于这一证据,大多数主要指南都对糖尿病患者的SBP目标值进行了修订。然而,与其他种族相比,亚洲人中SBP与中风之间的关联更为陡峭,中风是心血管疾病死亡的主要原因。这表明亚洲地区的血压目标应针对预防中风进行调整。在ACCORD研究中,强化血压治疗与总中风和非致命性中风的显著减少相关。ACCORD研究的结果得到了替米沙坦单药及与雷米普利联合应用全球终点试验(ONTARGET)研究的亚组分析的支持,该分析表明,在糖尿病患者中,SBP值降至115 mmHg时中风风险持续降低,且无J曲线证据。由于糖尿病与潜在的冠状动脉疾病高度相关,人们有理由担心血压过度降低会产生不良反应。在对国际维拉帕米缓释片-群多普利(INVEST)研究中纳入的6400名糖尿病受试者进行的事后分析中,SBP低于110 mmHg的受试者全因死亡率显著增加。在ONTARGET研究中,在任何实现的SBP水平下,舒张压(DBP)低于67 mmHg都与心血管结局风险增加相关。因此,对于患有冠状动脉疾病的糖尿病患者,谨慎的做法是将SBP目标设定为130 - 140 mmHg,DBP设定为60 mmHg以上。总之,已发现高血压与糖尿病相关,与心血管事件风险升高显著相关。与其他种族相比,亚洲人中中风与血压之间的关联更强,因此应考虑将亚洲人的血压目标设定为130/80 mmHg。